Successful treatment of multifocal pigmented basal cell carcinomas with the application of topical 5% imiquimod cream

Plachouri, Kerasia‐Maria; Balasis, Stauros; Mallioris, Athanasios Fotopoulos; Koumoundourou, Dimitra; Georgiou, Sophia

doi:10.1111/dth.12685

Cited by 2 publications

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the absence of tumor invasion also allows basal cell carcinoma in situ to be amendable to non-surgical and topical interventions such as photodynamic therapy following the application of photosensitizers and utilizing either 5% 5-fluorouracil cream or 5% imiquimod cream. In addition, albeit less frequently utilized, in situ basal cell carcinoma has also been found to be successfully treated with either intralesional interferon alpha or superficial radiotherapy [13][14][15][16][17].…”

Section: Featuresmentioning

confidence: 99%

Cutaneous Basal Cell Carcinoma In Situ: A Case Series

Cohen¹

2022

Cureus

View full text Add to dashboard Cite

Basal cell carcinoma, squamous cell carcinoma, and melanoma are three types of skin cancers. Skin cancers present as either non-invasive malignancies or invasive neoplasms. The non-invasive malignancies are referred to as carcinoma in situ; they only have cancer cells that are restricted to the epidermis and are not present as single tumor cells or independent nests of malignant cells in the underlying dermis. In contrast, invasive neoplasms demonstrate individual malignant cells or aggregates of tumor cells or both that are found in the dermis; in addition, cancer cells may also be located in the overlying epidermis. The features of three men with basal cell carcinoma in situ of the skin are described in this case series. Each of their tumors morphologically appeared as a red, scaly or non-scaly, and superficial plaque on the abdomen or the back; the neoplasm was successfully treated without recurrence by either surgical excision or by topical 5% imiquimod cream. Cutaneous basal cell carcinoma in situ has characteristic morphologic and pathologic findings. Clinically, cancer most commonly appears as a thin, smooth-surfaced or scaly, and as an erythematous plaque on the trunk. Microscopic examination shows multiple sites of basaloid tumor cells that either nearly filled the epidermis and/or replaced the lower layers of the epidermis; the aggregates of tumor cells may expand the epidermis and display slight extension into the papillary dermis. However, there is no contiguous invasion of the tumor cells from the overlying epidermis into the underlying dermis. Palisading of the peripheral tumor cells is noted; in addition, focally, retraction of the dermal stroma from the tumor is also frequently present. Lymphocytic inflammation may also be present in the upper dermis. Similar to the reported patients, since basal cell carcinoma in situ of the skin is only localized to the epidermis, several therapeutic modalities are available to effectively treat the cancer. However, if the basal cell carcinoma in situ represents the superficial portion of a basal cell carcinoma of mixed histology, tumor persistence or recurrence may occur if a more conservative approach to treatment is utilized that does not adequately treat the unsuspected and more aggressive pathologic subtype of basal cell carcinoma in the underlying dermis. In summary, basal cell carcinoma in situ of the skin has a unique clinicopathologic correlation of morphology, histology, tumor biology, and response to treatment; indeed, tumors that were previously classified as superficial basal cell carcinoma are more appropriately designated as cutaneous basal cell carcinoma in situ.

show abstract

Section: Featuresmentioning

confidence: 99%

Cutaneous Basal Cell Carcinoma In Situ: A Case Series

Cohen¹

2022

Cureus

View full text Add to dashboard Cite

show abstract

The Evolving Story of Laser Therapeutics for Basal Cell Carcinoma

2020

View full text Add to dashboard Cite

BACKGROUND The increasing burden from basal cell carcinoma (BCC) has stimulated the development of alternative treatments for these tumors. OBJECTIVE This review focuses on upcoming laser treatments for BCC and highlights the limitations of these therapies. METHODS A PUBMED search was conducted for articles on laser therapy of BCC. Key studies involving lasers to treat BCC were reviewed. Novel approaches to BCC are also described. RESULTS Vascular-specific laser therapy has increasingly been studied as an addition in the therapeutic armamentarium of BCC. Although these studies demonstrate efficacy for nonaggressive BCC, optimization of this technique is ongoing to minimize scarring. A more targeted approach to the treatment of BCC, such as immunized photothermal therapy or laser-assisted chemotherapeutic delivery, may result in less scarring, while maintaining efficacy similar to that of lasers targeting tumor vasculature. CONCLUSION Vascular-specific laser therapies show promise in treating low-risk BCC; however, scarring is not an uncommon adverse event. Although only animal studies have been performed to date, laser-activated gold nanoparticle therapy and laser-assisted drug delivery of vismodegib are potential therapies that theoretically confer a more selective approach. Laser modalities demonstrate promise in the treatment of nonaggressive BCC, although long-term studies have yet to be published.

show abstract

Successful treatment of multifocal pigmented basal cell carcinomas with the application of topical 5% imiquimod cream

Cited by 2 publications

References 12 publications

Cutaneous Basal Cell Carcinoma In Situ: A Case Series

Cutaneous Basal Cell Carcinoma In Situ: A Case Series

The Evolving Story of Laser Therapeutics for Basal Cell Carcinoma

Contact Info

Product

Resources

About